Tolerance and Loss of Beneficial Effect During Migraine Prophylaxis: Clinical Considerations
- 2 September 2011
- journal article
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 51 (8) , 1336-1345
Abstract
A familiar situation in migraine treatment is the patient with an initial positive response to prophylactic drug therapy who later experiences relapse. The goals of this paper are to provide a theoretical framework to help doctors think about this problem, to evaluate factors and response patterns that may be associated with different causes of relapse, and to suggest clinical strategies that may aid in its management. Six key explanations for loss of benefit from prophylactic therapy are: (1) pharmacokinetic, pharmacodynamic, and behavioral drug tolerance; (2) non‐specific or placebo effects; (3) natural variability in disease activity; (4) disease progression; (5) inaccurate recall of treatment effects; and (6) drug delivery problems. Current options for patients who experience loss of benefit from prophylactic therapy include traditional techniques such as switching, re‐trying, rotating, or combining drugs. Selected behavioral and environmental treatment techniques might also be useful. We describe a practical, structured approach to evaluation and management of relapse with migraine prophylaxis.Keywords
This publication has 41 references indexed in Scilit:
- Polytherapy for the prophylaxis of chronic migraine: an Italian surveyNeurological Sciences, 2011
- N-of-1 Trials: Not Just for AcademicsJournal of General Internal Medicine, 2010
- Biological, clinical, and ethical advances of placebo effectsThe Lancet, 2010
- Components of placebo effect: randomised controlled trial in patients with irritable bowel syndromeBMJ, 2008
- Frovatriptan vs. transdermal oestrogens or naproxen sodium for the prophylaxis of menstrual migraineThe Journal of Headache and Pain, 2007
- Drug-Induced Epigenetic Changes Produce Drug TolerancePLOS Biology, 2007
- Formation of neutralizing antibodies in patients receiving botulinum toxin type a for treatment of poststroke spasticity: A pooled-data analysis of three clinical trialsClinical Therapeutics, 2007
- Is Tolerance to Antiepileptic Drugs Clinically Relevant?Epilepsia, 2006
- Dextroamphetamine Pilot Crossover Trials and n of 1 Trials in Patients With Chronic Tension‐Type and Migraine HeadacheHeadache: The Journal of Head and Face Pain, 2004
- The Doctor, His Patient, and the IllnessThe American Journal of the Medical Sciences, 1957